Pricing Log in Create free account
Friday 6 November 2026 Export SYRE’s income statement to Excel — free account

Spyre Therapeutics, Inc.

SYRE Healthcare Biotechnology

Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022.

EPS
−624.8%
Free cash flow
−108.8%

Quarter to September 2026, against a year earlier

102.07 5.48 +5.67%
Market cap
$9.2B
P/E
0.0×
Fwd P/E
−4.8×
Dividend yield
—
F-score
3/9
Altman Z
−3.82
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Spyre Therapeutics, Inc. 10-Q filed Nov 3, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:01 PM ET · Document on sec.gov · Filing index

Red flags

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 4, 2026: 19 added · 24 removed · 43 modified; 6 with only figures updated; 2 moved without change

  1. Modified · Overview

    We are a clinical stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Our pipeline includes extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-23 in development IL-17A/F (each as defined below), as monotherapies and pair-wise combinationswell as rational combination programs.

85 more changes in this Item, word by word, in Powerpack.